Drug Trial Radar · NCT05321082
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,178
Actual
Start
Nov 16, 2022
Primary completion
Dec 18, 2024
Study completion Apr 14, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study. The purpose of this study is to find out whether a medicine called BI 1015550 helps people with PF-ILD. Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of BI 1015550 as tablets twice a day. Participants in the placebo group take placebo tablets twice a day. Placebo tablets look like BI 1015550 tablets but do not contain any medicine. Participants are in the study for up to two and a half years. During the first year, they visit the study site 10 times. Afterwards, they visit the study site every 3 months. The doctors regularly test participants' lung function. The results of the lung function tests are compared between the groups. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Lung Diseases, Interstitial
Interventions
BI 1015550Drug
Participants received film-coated nerandomilast tablets orally, twice daily, at doses of either 9 mg or 18 mg, in the morning and in the evening.
PlaceboDrug
Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally, twice daily, in the morning and in the evening.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52Time frame: The MMRM model is a longitudinal analysis, and it incorporated FVC measurements change from baseline at Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. Data presented is the FVC adjusted change from baseline at Week 52.
Locations
400 sites in 45 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Arizona
Tucson, Arizona
University of Southern California
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California
University of California Davis
Sacramento, California
National Jewish Health
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
Christiana Hospital
Newark, Delaware
St. Francis Medical Institute
Clearwater, Florida
University of Florida Health Shands Hospital
Gainesville, Florida
Clinical Research Specialists LLC
Kissimmee, Florida
Advanced Pulmonary Research Institute
Loxahatchee Groves, Florida
Destin Pulmonary Critical Care
Santa Rosa Beach, Florida
Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead
Atlanta, Georgia
The Emory Clinic
Atlanta, Georgia
Evanston Hospital Pulmonary Clinic
Evanston, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Tulane University Hospital and Clinic
New Orleans, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
St. Elizabeth's Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Infinity Medical Research
North Dartmouth, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Beaumont Health
Royal Oak, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic, Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Renown Regional Medical Center
Reno, Nevada
Stony Brook University Medical Center
Commack, New York
Lenox Hill Hospital
New York, New York
Columbia University Medical Center-New York Presbyterian Hospital
New York, New York
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Southeastern Research Center-Winston-Salem-61365
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Showing 40 of 400 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.